JP2003504312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003504312A5 JP2003504312A5 JP2001504417A JP2001504417A JP2003504312A5 JP 2003504312 A5 JP2003504312 A5 JP 2003504312A5 JP 2001504417 A JP2001504417 A JP 2001504417A JP 2001504417 A JP2001504417 A JP 2001504417A JP 2003504312 A5 JP2003504312 A5 JP 2003504312A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- drug conjugate
- dextrin
- reagent
- mol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001353 Dextrin Polymers 0.000 description 16
- 239000004375 Dextrin Substances 0.000 description 16
- 235000019425 dextrin Nutrition 0.000 description 16
- 239000000562 conjugate Substances 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 239000000580 polymer-drug conjugate Substances 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- PQFMNVGMJJMLAE-QMMMGPOBSA-N L-tyrosinamide Chemical group NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PQFMNVGMJJMLAE-QMMMGPOBSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9914187.1 | 1999-06-18 | ||
| GBGB9914187.1A GB9914187D0 (en) | 1999-06-18 | 1999-06-18 | Biologically active materials |
| GB9930252.3 | 1999-12-22 | ||
| GBGB9930252.3A GB9930252D0 (en) | 1999-12-22 | 1999-12-22 | Biologically active molecules |
| PCT/GB2000/002216 WO2000078355A2 (en) | 1999-06-18 | 2000-06-19 | Biologically active materials |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003504312A JP2003504312A (ja) | 2003-02-04 |
| JP2003504312A5 true JP2003504312A5 (https=) | 2007-07-26 |
Family
ID=26315678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001504417A Pending JP2003504312A (ja) | 1999-06-18 | 2000-06-19 | 生物学的に活性な材料 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6818630B1 (https=) |
| EP (1) | EP1198253A2 (https=) |
| JP (1) | JP2003504312A (https=) |
| AU (1) | AU783886B2 (https=) |
| CA (1) | CA2374548A1 (https=) |
| HK (1) | HK1047884A1 (https=) |
| IL (1) | IL146795A0 (https=) |
| MX (1) | MXPA01013276A (https=) |
| NO (1) | NO20016147L (https=) |
| NZ (1) | NZ515999A (https=) |
| WO (1) | WO2000078355A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| EP1315777B1 (en) | 2000-09-06 | 2007-10-31 | AP Pharma, Inc. | Degradable polyacetal polymers |
| DE10112825A1 (de) | 2001-03-16 | 2002-10-02 | Fresenius Kabi De Gmbh | HESylierung von Wirkstoffen in wässriger Lösung |
| DE10129369C1 (de) | 2001-06-21 | 2003-03-06 | Fresenius Kabi De Gmbh | Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats |
| AU2003209227A1 (en) | 2002-01-14 | 2003-07-30 | The General Hospital Corporation | Biodegradable polyketal polymers and methods for their formation and use |
| DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
| US8030459B2 (en) | 2002-07-19 | 2011-10-04 | The General Hospital Corporation | Oxime conjugates and methods for their formation and use |
| ATE409048T1 (de) | 2002-10-08 | 2008-10-15 | Fresenius Kabi De Gmbh | Pharmazeutisch aktive oligosaccharid-conjugate |
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| AU2004270251B2 (en) * | 2003-09-05 | 2011-03-31 | The General Hospital Corporation | Polyacetal drug conjugates as release system |
| WO2010068759A1 (en) | 2008-12-10 | 2010-06-17 | Mersana Therapeutics, Inc. | Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates |
| KR102366322B1 (ko) | 2020-07-31 | 2022-02-22 | 주식회사 다산네트웍스 | 전기자전거 주행시스템 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0477931B1 (en) | 1990-09-28 | 1994-08-17 | Mercian Corporation | Novel adriamycin derivatives |
| WO1995005199A1 (en) | 1993-08-19 | 1995-02-23 | Dextran Products Limited | Pharmaceutical preparation and a process for making same |
| IT1281877B1 (it) | 1995-05-10 | 1998-03-03 | Fidia Advanced Biopolymers Srl | Sali di metalli pesanti di succinil derivati dell'acido ialuronico e loro impiego come potenziali agenti terapeutici |
| AU8025998A (en) * | 1997-06-12 | 1998-12-30 | Ml Laboratories Plc | Biologically active materials |
-
2000
- 2000-06-19 IL IL14679500A patent/IL146795A0/xx unknown
- 2000-06-19 US US10/018,608 patent/US6818630B1/en not_active Expired - Fee Related
- 2000-06-19 CA CA002374548A patent/CA2374548A1/en not_active Abandoned
- 2000-06-19 MX MXPA01013276A patent/MXPA01013276A/es unknown
- 2000-06-19 EP EP00938905A patent/EP1198253A2/en not_active Withdrawn
- 2000-06-19 AU AU54130/00A patent/AU783886B2/en not_active Ceased
- 2000-06-19 HK HK02107706.8A patent/HK1047884A1/zh unknown
- 2000-06-19 JP JP2001504417A patent/JP2003504312A/ja active Pending
- 2000-06-19 NZ NZ515999A patent/NZ515999A/xx unknown
- 2000-06-19 WO PCT/GB2000/002216 patent/WO2000078355A2/en not_active Ceased
-
2001
- 2001-12-17 NO NO20016147A patent/NO20016147L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102516417B (zh) | 用于传递治疗剂的以环糊精为基础的聚合物 | |
| Uhrich et al. | Polymeric systems for controlled drug release | |
| JP2003504312A5 (https=) | ||
| JP2003113113A5 (https=) | ||
| EP2626368A3 (en) | Insulin-oligomer conjugates, formulations and uses thereof | |
| EP2316490A3 (en) | Methods and compositions for enhanced delivery of bioactive molecules | |
| JP2002504519A (ja) | 新規なペプチド共重合体組成物 | |
| JP4027663B2 (ja) | ポリマー安定化神経ペプチド | |
| JPH02300133A (ja) | 水溶性高分子化医薬製剤 | |
| Temming et al. | Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels | |
| JP5856069B2 (ja) | 新規なシチジン系代謝拮抗剤の高分子誘導体 | |
| JP2003511349A (ja) | 薬剤担体としてのポリ（ジペプチド） | |
| KR101066763B1 (ko) | 온도 반응성 전달계 | |
| WO1996016541A1 (en) | Polymer linked biological agents | |
| RU2004114225A (ru) | Перорально вводимые жидкие композиции, включающие гвайфенезин и блок-сополимеры полиоксиалкилена | |
| JP2002502825A (ja) | 経口運搬用共重合体組成物 | |
| EP2283872A3 (en) | Non-covalent bioconjugates useful for diagnosis and therapy | |
| JP2008534747A (ja) | Ｐｅｇ−ポリアセタールグラフトコポリマーおよびｐｅｇ−ポリアセタール−ｐｏｅグラフトコポリマーならびに医薬組成物 | |
| Duncan | N-(2-Hydroxypropyl) methacrylamide copolymer conjugates | |
| Hegde et al. | An update on design and pharmacology of dendritic poly (l-lysine) | |
| WO2014073447A1 (ja) | カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途 | |
| CA2219777A1 (en) | Nanoparticles for oral administration of pharmaceutical agents of low solubility | |
| Gorain et al. | Polymeric micelle-based drug delivery systems for tuberculosis treatment | |
| CN119212725A (zh) | 聚合物纳米聚集体药物组合物及其用途 | |
| WO2001060412A3 (en) | Modification of biopolymers for improved drug delivery |